meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic, hormone-sensitive prostate cancer
11
renal cell cancer (RCC)
HIF-2α inhibitor
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
avelumab based treatment
avelumab plus axitinib
nivolumab based treatment
nivolumab alone
nivolumab 2 mg/kg
nivolumab plus cabozantinib
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus axitinib
pembrolizumab plus lenvatinib
Tislelizumab
toripalimab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
mTOR inhibitors
everolimus
lenvatinib plus everolimus
VEGF(R) inhibitor
cabozantinib
lenvatinib
lenvatinib in association
no study with result for this clinical condition